Dobutamine Could Reduce Kidney Injury in Septic Shock

Adults with septic shock needing surgery saw less postoperative kidney injury in a randomized trial, though the findings need confirmation.

Updated on Nov. 4, 2026 in Heart Disease

Bold flat-color vector editorial illustration of two unlabeled glass infusion bottles above a simplified kidney with branching vessels, evoking kidney protection during septic shock surgery.
A randomized trial in JAMA found adding intraoperative dobutamine to norepinephrine was linked to less postoperative kidney injury in adults with septic shock undergoing surgery. AI Illustration. Upload story photo >

A randomized clinical trial published in JAMA found that adding intraoperative dobutamine to norepinephrine was associated with less postoperative acute kidney injury in adults with septic shock undergoing surgical source control. The trial, conducted at 39 hospitals in China, was published October 14, 2026, and its findings may not extend to septic shock patients who do not need surgery.

Why it matters

Acute kidney injury is a common and serious complication of septic shock, and the trial suggests a possible way to lower its frequency during surgery for infection. The result matters most for clinicians and patients facing emergency source-control procedures, where kidney protection is a key concern. Because the trial was open-label and several findings were post hoc, the results are best viewed as a strong signal that needs confirmation.

This open-label, multicenter randomized trial enrolled 584 adults with septic shock across 39 hospitals in China, with a median age of 67.5 years. The adjusted risk of postoperative acute kidney injury was 0.64 for the dobutamine plus norepinephrine group compared with norepinephrine alone, though the trial's open-label design and post hoc subgroup analyses limit how firmly the results can be interpreted.

The players

JAMA

The Journal of the American Medical Association is a leading peer-reviewed medical journal that published the trial.

Zhejiang University School of Medicine

The academic institution of the lead investigator, a major medical research center in China.

The details

Septic shock can reduce blood flow to the kidneys, and surgery adds further stress to organs already under strain. In this trial, intravenous dobutamine, up to 5 μg/kg/min, was given during surgery alongside norepinephrine. Dobutamine acts on β-adrenergic receptors, which may help improve tissue perfusion, while norepinephrine continues to support blood pressure. The combination appeared to reduce kidney injury but increased tachycardia, a faster-than-normal heart rate.

Timeline

  1. October 14, 2026: Trial results were published online in JAMA.

  2. November 4, 2026: Renal and Urology News published an article on the trial.

Health Landscape

Dobutamine is currently recommended for septic shock with cardiac dysfunction and persistent hypoperfusion, though that recommendation rests on very low-certainty evidence. This trial tests a new use of the drug, intraoperative kidney protection, and adds to a growing body of research on managing blood flow in severe infection.

If you or a family member is facing emergency surgery for a serious infection, the trial suggests kidney protection during surgery is an active area of research worth raising with the care team. Anyone with a history of heart rhythm problems should note the higher rate of rapid heartbeat seen with the combination, and discuss it with a clinician.

The takeaway

Kidney injury is a serious complication of septic shock, and this trial points to intraoperative dobutamine as a possible way to reduce it, though the benefit has not been confirmed for all patients. Anyone with questions about how this might apply to their care should raise them with their physician.

Further reading

For broader background on how cardiovascular treatments are studied and applied, see Heart Disease.

Source note: This article includes information reported by Renal and Urology News.